RU2011111640A - Антитела против cd5 - Google Patents
Антитела против cd5 Download PDFInfo
- Publication number
- RU2011111640A RU2011111640A RU2011111640/10A RU2011111640A RU2011111640A RU 2011111640 A RU2011111640 A RU 2011111640A RU 2011111640/10 A RU2011111640/10 A RU 2011111640/10A RU 2011111640 A RU2011111640 A RU 2011111640A RU 2011111640 A RU2011111640 A RU 2011111640A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- antibodies
- composition according
- antibody composition
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract 91
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 13
- 238000000034 method Methods 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 101100273730 Homo sapiens CD5 gene Proteins 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000010354 integration Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801191 | 2008-08-29 | ||
| DKPA200801191 | 2008-08-29 | ||
| US9370008P | 2008-09-02 | 2008-09-02 | |
| US61/093,700 | 2008-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011111640A true RU2011111640A (ru) | 2012-10-10 |
Family
ID=40677719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011111640/10A RU2011111640A (ru) | 2008-08-29 | 2009-08-28 | Антитела против cd5 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110250203A1 (OSRAM) |
| EP (1) | EP2328932A1 (OSRAM) |
| JP (1) | JP2012500815A (OSRAM) |
| KR (1) | KR20110050541A (OSRAM) |
| CN (1) | CN102137873A (OSRAM) |
| AU (1) | AU2009287164A1 (OSRAM) |
| BR (1) | BRPI0917148A2 (OSRAM) |
| CA (1) | CA2735279A1 (OSRAM) |
| IL (1) | IL209975A0 (OSRAM) |
| MX (1) | MX2011000970A (OSRAM) |
| NZ (1) | NZ591153A (OSRAM) |
| RU (1) | RU2011111640A (OSRAM) |
| TW (1) | TW201011045A (OSRAM) |
| WO (1) | WO2010022737A1 (OSRAM) |
| ZA (1) | ZA201100300B (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012020790B1 (pt) | 2010-02-18 | 2021-09-28 | The Regents Of The University Of California | Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica |
| JP2014510080A (ja) * | 2011-03-09 | 2014-04-24 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| WO2013023162A2 (en) * | 2011-08-10 | 2013-02-14 | Genus Oncology, Llc | Anti-muc1 antibodies for cancer diagnostics |
| CN103857696B (zh) | 2011-08-17 | 2017-07-04 | 加利福尼亚大学董事会 | 结合整合素αVβ8的抗体 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CN102786595B (zh) * | 2012-08-03 | 2014-04-23 | 无锡傲锐东源生物科技有限公司 | 抗cd5蛋白单克隆抗体及其用途 |
| EA031025B1 (ru) | 2012-12-21 | 2018-11-30 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные с ними композиции и способы |
| ES2871816T3 (es) * | 2012-12-27 | 2021-11-02 | Sanofi Sa | Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CA2939034A1 (en) * | 2014-02-19 | 2015-08-27 | Cangene Corporation | Methods of modulating an immune response |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
| HRP20211273T1 (hr) | 2014-11-26 | 2021-11-12 | Xencor, Inc. | Heterodimerna protutijela koja vežu cd3 i cd20 |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US10786549B2 (en) | 2015-04-23 | 2020-09-29 | Baylor College Of Medicine | CD5 chimeric antigen receptor for adoptive T cell therapy |
| WO2017214285A1 (en) * | 2016-06-07 | 2017-12-14 | Eynav Klechevsky | Detection of cd5 and methods and compositions for modulating cd5 |
| EP3475304B1 (en) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
| WO2018052818A1 (en) | 2016-09-16 | 2018-03-22 | Henlix, Inc. | Anti-pd-1 antibodies |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| IL316155A (en) | 2017-11-29 | 2024-12-01 | Heidelberg Pharma Res | Compositions and Methods for the Depletion of CD5(PLUS) CELLS |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| WO2019204507A1 (en) * | 2018-04-18 | 2019-10-24 | Biomadison, Inc. | Methods for determining vaccine potency |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| US11673964B2 (en) | 2018-12-19 | 2023-06-13 | The Trustees Of The University Of Pennsylvania | Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias |
| CN115605491A (zh) | 2019-04-05 | 2023-01-13 | 刘扶东（Us） | 抗唾液酸酶的糖类、其制造方法及用途 |
| AU2020263959A1 (en) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| EP4025686A4 (en) | 2019-09-03 | 2023-09-13 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN116075315B (zh) | 2020-05-08 | 2025-12-19 | 周美吟 | 嵌合流感疫苗 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| WO2021231982A1 (en) * | 2020-05-14 | 2021-11-18 | City Of Hope | Smc1a antibodies and uses thereof |
| EP3915641A1 (en) * | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anti-cd5 antibodies and methods of use thereof |
| JP2023538108A (ja) * | 2020-08-21 | 2023-09-06 | シティ・オブ・ホープ | 抗ｃｄ５抗体組成物及びその使用 |
| JP2023541458A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ５修飾のための化合物および方法 |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| US20220144956A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
| WO2022127844A1 (zh) * | 2020-12-17 | 2022-06-23 | 江苏先声药业有限公司 | Cd5抗体及其应用 |
| EP4279508A4 (en) * | 2021-01-12 | 2024-12-04 | Nanjing Iaso Biotechnology Co., Ltd. | Cd5-targeting fully humanized antibody |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| US12257298B2 (en) | 2021-04-12 | 2025-03-25 | Academia Sinica | Coronavirus vaccine |
| WO2022231298A1 (ko) * | 2021-04-29 | 2022-11-03 | 한국생명공학연구원 | 신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포 |
| JP2024518100A (ja) | 2021-05-11 | 2024-04-24 | マイエロイド・セラピューティクス，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| CN113105547B (zh) * | 2021-05-18 | 2022-04-08 | 福州迈新生物技术开发有限公司 | 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用 |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US12077597B2 (en) | 2021-11-24 | 2024-09-03 | International-Drug-Development-Biotech | Anti-CD5 antibodies and methods of use thereof |
| CN120787235A (zh) * | 2021-12-27 | 2025-10-14 | 周美吟 | Sars-cov-2棘蛋白特异性抗体及其用途 |
| WO2024039683A1 (en) * | 2022-08-15 | 2024-02-22 | Myeloid Therapeutics, Inc. | Compositions and methods for conditioning patients for cell therapy |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CA3268566A1 (en) | 2023-04-08 | 2024-10-17 | Rock Biomedical Inc. | METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2024258967A1 (en) * | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4312916C2 (de) * | 1993-04-14 | 1995-03-23 | Fresenius Ag | Arzneimittel zur Behandlung von Immunreaktionen |
-
2009
- 2009-08-28 EP EP09809275A patent/EP2328932A1/en not_active Withdrawn
- 2009-08-28 MX MX2011000970A patent/MX2011000970A/es not_active Application Discontinuation
- 2009-08-28 BR BRPI0917148A patent/BRPI0917148A2/pt not_active IP Right Cessation
- 2009-08-28 JP JP2011524187A patent/JP2012500815A/ja not_active Withdrawn
- 2009-08-28 US US13/061,420 patent/US20110250203A1/en not_active Abandoned
- 2009-08-28 CN CN2009801336869A patent/CN102137873A/zh active Pending
- 2009-08-28 NZ NZ591153A patent/NZ591153A/xx not_active IP Right Cessation
- 2009-08-28 WO PCT/DK2009/050218 patent/WO2010022737A1/en not_active Ceased
- 2009-08-28 CA CA2735279A patent/CA2735279A1/en not_active Abandoned
- 2009-08-28 KR KR1020117007230A patent/KR20110050541A/ko not_active Withdrawn
- 2009-08-28 AU AU2009287164A patent/AU2009287164A1/en not_active Abandoned
- 2009-08-28 RU RU2011111640/10A patent/RU2011111640A/ru not_active Application Discontinuation
- 2009-08-31 TW TW098129192A patent/TW201011045A/zh unknown
-
2010
- 2010-12-13 IL IL209975A patent/IL209975A0/en unknown
-
2011
- 2011-01-11 ZA ZA2011/00300A patent/ZA201100300B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110050541A (ko) | 2011-05-13 |
| AU2009287164A1 (en) | 2010-03-04 |
| NZ591153A (en) | 2012-12-21 |
| MX2011000970A (es) | 2011-03-15 |
| BRPI0917148A2 (pt) | 2015-12-01 |
| WO2010022737A1 (en) | 2010-03-04 |
| JP2012500815A (ja) | 2012-01-12 |
| IL209975A0 (en) | 2011-02-28 |
| EP2328932A1 (en) | 2011-06-08 |
| ZA201100300B (en) | 2012-01-25 |
| US20110250203A1 (en) | 2011-10-13 |
| CN102137873A (zh) | 2011-07-27 |
| TW201011045A (en) | 2010-03-16 |
| CA2735279A1 (en) | 2010-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011111640A (ru) | Антитела против cd5 | |
| US20250026823A1 (en) | Bispecific igg antibodies as t cell engagers | |
| US20230077648A1 (en) | Heterodimeric Bispecific Antibodies | |
| JP2012500815A5 (OSRAM) | ||
| JP6700354B2 (ja) | ヘテロ二量体性二重特異性抗体 | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2022550832A (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| JP2010535012A5 (OSRAM) | ||
| RU2016151645A (ru) | Биспецифические гетеродимерные диантитела и их применение | |
| RU2013157040A (ru) | Поливалентная антиген-связывающая fv-молекула | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| WO2022256563A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| RU2012128343A (ru) | АНТИ-С4.4а АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| Li et al. | One-domain CD4 fused to human anti-CD16 antibody domain mediates effective killing of HIV-1-infected cells | |
| RU2012136234A (ru) | Антагонистические антитела против рецептора il-7 и способы | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| JP2021501566A5 (OSRAM) | ||
| JP7773372B2 (ja) | 線維芽細胞活性化タンパク質結合物質およびその使用 | |
| GB2613464A (en) | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof | |
| KR20240103034A (ko) | Tigit 및 pd-l1에 대한 이중특이적 항체, 그의 의약 조성물, 및 그의 용도 | |
| CN111662382A (zh) | 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用 | |
| US20210214454A1 (en) | Anti-cd40 antibodies and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131127 |